This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Monday, March 24, 2014
Gilead scrambles toward hep C cure-all with next-gen combo pill
"This molecule is very important (for) Gilead longer term because the
"holy grail" of hep C treatment would be a pan-genotypic one pill once
per day regimen," Schoenebaum wrote in a hastily penned note to
investors Monday morning....
The biotech--under intense criticism for pricing Sovaldi at $84,000 in
the U.S. for the 12-week treatment--posted an abstract for the upcoming
meeting of the European Association for the Study of the Liver that
outlined 100% cure rates among small groups of patients across 6
genotypes taking one of two doses of a Sovaldi combination treatment.
The big add here is GS-5816, a next-gen NS5A inhibitor that added the
essential ingredient for a new regimen that promises to eliminate any
need for interferon as well as ribavirin.
No comments:
Post a Comment